Investor Relations



    We welcome 2 new acquisitions to the Swedencare family –
    Nutravet & Animal Pharm (24 Sept 2020):
       (Print)

CEO Comments

“A very eventful quarter with new records”

HÅKAN LAGERBERG, CEO – SWEDENCARE AB (PUBL)


SALES AND EARNINGS (Q3/2020):

Net SalesQ3 2020

69 566

KSEK ( 119%)

EBITQ3 2020

18 642

KSEK (26.8%)

Share this information:


Company Information


“A very eventful quarter with new records”

THIRD QUARTER: July 1st – September 30th 2020

(Numbers in parentheses refer to outcomes during the corresponding period of the previous year.)

•  Net revenue amounted to 69 566 KSEK (31 759 KSEK), a increase of 119%.
•  Organic, currency-adjusted growth amounted to 27% .
•  Operating profit begore depreciation (EBITDA) amounted to 20 870 KSEK (11 311 KSEK),
corresponding to a increase of 84% corresponding to an EBITDA-margin of 30,0% (35,6%).
•  Operating profit after depreciation (EBIT) amounted to 18 642 KSEK (10 995 KSEK),
corresponding to a increase of 70% and an EBIT-margin of 26,8% (34,6%).
•  Profit after tax amounted to 14 497 KSEK (8 875 KSEK).
•  Earnings per share, based on 17 432 415 shares 0,83 SEK (0.56 SEK).
•  As of September 30th 2020 cash amounted to 408 661 KSEK (40 063 KSEK).
•  Costs in connection with the acquisition of Nutravet UK and Animal Pharmaceuticals operations amounted to 1 515 KSEK.
•  Adjusted for this, EBITDA amounted to 22 385 KSEK corresponding to an EBIT-margin of 32.2%
and EBIT to 20 157 KSEK corresponding to an EBIT-margin of 29.0%.

FIRST 9-MONTHS: January 1st – September 30th 2020

(Numbers in parentheses refer to outcomes during the corresponding period of the previous year.)

•  Net revenue amounted to 139 306 TSEK (92 686 TSEK), an increase of 50%.
•  Organic, currency-adjusted growth amounted to 14% .
•  Operating profit before depreciation (EBITDA) amounted to 38 724 TSEK (31 286 TSEK),
corresponding to an increase of 24% corresponding to an EBITDA-margin of 27,8% (33,7%).
•  Operating profit after depreciation (EBIT) amounted to 35 027 TSEK (30 331 TSEK),
corresponding to an increase of 16% and an EBIT-margin of 25.1% (32,7%).
•  Profit after tax amounted to 28 083 TSEK (24 192 TSEK).
•  Earnings per share calculated on 16 382 272 shares 1,71 SEK (1.53 SEK).
•  Cash flow from operating activities amounted to 20 444 TSEK (24 740 TSEK).
•  Foreign exchange gains amounted to 656 TSEK.

Significant events during the third quarter:

•  Swedencare AB (publ) acquires operations from a leading Brittish pet health care company.

•  Swedencare AB (publ) acquires operations from an American pet health care company with a focus on the veterinary channel.

•  Swedencare AB (publ) carries out a directed new issue of 2 000 000 shares and is thus provided with approximately 340 MSEK, which after issue costs of 4,7 MSEK, gave a net contribution of 335,3 MSEK to partly finance acquisitions.

Significant events after the third quarter:

•  Swedencare AB (publ) took, on October 1st, over the businesses acquired on September 24th.

Words from the CEO:

To say that this Q3 was one of the most eventful quarters in the history of Swedencare is by no means an exaggeration. Many exciting things have happened and here is my attempt to briefly describe recent events.

The revenue of the third quarter was 69,6 MSEK, which is an increase of 119% compared to Q3 2019. The EBITDA results increased by 84% to 20,9 MSEK, corresponding to a margin of 30%. The result was affected by costs amounting to approximately 1,5 MSEK due to the acquisitions of Animal Pharmaceutical and Nutravet. When adjusting to these acquisition costs we reach an EBITDA margin of 32,2%, well exceeding our current long-term goal of 25% – despite the current changes and challenges in the world. As I wrote in my last report, we had a strong recovery at the end of Q2 and it has been maintained all through Q3.

The he fact that we produced a record high report as regards to revenues and profits was expected due to our acquisition of Stratford, which is included in the numbers from July 1st, 2020. But delivering a 27% organic growth is truly a proof of strength, particularly in regard to the current situation worldwide. Even when extracting the Stratford addition, we have delivered record high revenues as well as profits.

The currently increasing spread of the Corona virus effects many markets globally, but as of yet we have not noticed any major effects in sales. With exhibitions and events cancelled and most customer meetings held digitally it is difficult to foresee exactly if and how these changes will affect us, but I don´t think they will stop our growth to any major extent. When it comes to addressable markets the number of pets has increased in almost all markets and as pet parents now value and spend even more time with their four-legged friends even stronger bonds are made, a factor that is positive for us as a distributor of premium products.

On the marketing side the company’s full focus lies on brand building and directed activities to generate sales for us and our partners worldwide. We are in the midst of developing a new brand name platform, new website as well as developing social media brand building, advertising and expanding our cooperation with influencers.

Due to the current Corona related restrictions the integration of Stratford had to be made over distance, but the process has gone just as well as expected. Our main focuses have been sales co-ops, product training and the transfer of some of SwedencareUSA´s veterinary customers to Stratford. By the end of the quarter the full range of powder products were delivered to Stratford, who will be launching them to the veterinary segment all over the US. We have also picked out some of Stratford´s best products to be launched under the Swedencare brand name to certain important ”Pet Specialty” customers of SwedencareUSA.

As previously stated, this quarter was strong and in the North American market both our subsidiaries had record quarters with growth amounting to over 30%. The inflow of new B2B customers was strong and SwedencareUSA added amongst others Woof Gang Bakery with 130 stores and Mondue with 60 stores to their customer list while Stratford added a new veterinary chain with 75 clinics to theirs.

We keep expanding within online sales, which is to be expected as many clinics and physical shops have limitations in regard to opening hours and number of simultaneous visitors.

In the UK we see the same trend as in the US with over 30% growth and an increase in online sales. Our production facility in Ireland were quick to adapt to the Irish COVID restrictions which resulted in a temporary decrease in production during Q2 but are now back to full production and scheduling capacity. During Q3 the team has produced ProDen PlaqueOff® for a large number of internal markets and also supplied the demand amongst our external customers in the UK, Germany and the BeNeLux. The team has worked hard to meet the market demands and I am proud that Swedencare has such an effective production facility and organization in Ireland.

Our other subsidiaries keep developing strongly with high growth and record high months both in Spain and Greece. In France and the Nordics we see a slightly lower growth rate, but the trend is positive with a high number of pending orders and favorable prognosis for the next quarter. All subsidiaries had a larger demand than could be met for the products Dental Bones and Dental Bites. The pandemic caused us some production and delivery challenges, but as the quarter came to its end that situation was again going back towards normal.

In the rest of the world we have delivered to all large markets – Australia, Brazil, Russia, South Korea, Japan and China. We have received very encouraging reports from the first four countries where Q3, especially September, showed fantastic sales numbers for ProDen PlaqueOff®. The highest quarterly and month sales results shows that our targeted online marketing activities have had great impact. Our Dental Bones keep conquering new markets and in October we sent our first orders to Japan, a market in which we have very high expectations.

Not only did we experience a strongly increased “normal” business sentiment during Q3 – we also had some extraordinary intense activities when ending the quarter! The acquisitions of UK based Nutravet and American Animal Pharmaceuticals, both companies with strong positions within the veterinary sector, were made at the same time, both with take over from October 1st. The financing was mainly made by a directed new share issue where a large number of Swedish and international institutions took part.

Our acquisition strategy is based on a simple prevailing rule – we seek companies that are similar to ours in that they should be entrepreneurial, profitable with high growth rate and with owners/management that share our goal in creating a world leading group within the Pet Healthcare market. We have made a thorough review and I am certain that these two acquisitions will prove to be extremely successful when we look back a few years from now.

With Nutravet we gain the market leading nutraceutical company within Pet Healthcare in the UK, with an enormous potential for export. The founder, Matthew Shaw, who now is a major shareholder of Swedencare, has built an impressive product line, organization and network. Nutravet also has a unique agreement with the largest veterinary chain in Europe. Thus far product launch has been made to the UK clinics and the next phase includes launch to clinics in the other ten countries where the veterinary chain operates.

Animal Pharmaceuticals provides us with yet another veterinary focused company in the US which will have many synergies with Stratford with regards to organization, fulfillment, finance and sales. Jason Brown, who now is a major shareholder of Swedencare, founded the company and has run it successfully for 17 years. We have with these two American acquisitions reached a new level having added agreements with the three largest veterinary distributors in the US with sales adding up to almost 30 000 veterinary clinics. Brian (Stratford) and Jason (AP) will alongside Martin (SwedencareUSA) and their respective teams, represent a major part of Swedencare’s revenues with the US being our largest market, which is well in line with our ambition as the US is by far the largest Pet market in the world.

Given all of these changes in the company the only thing I find frustrating is not being able to travel and meet my new colleagues in person and not being able to have meetings with our customers, suppliers and other partners. I very much look forward to doing so when the situation allows it.

I am grateful for and equally humbled by the trust that the capital market has shown Swedencare and me as its CEO. I will continue to do my utmost to supersede your expectations and I am encouraged by working in such a fantastic and dynamic organization.

Best Regards,

Håkan Lagerberg, CEO
Malmö, October 22nd 2020

Read the half-year report in its entirety here:    (Print)    (Screen)

FOR FURTHER INFORMATION:
Håkan Lagerberg, CEO
Tel: +46 (0)735-170 170, E-mail: hakan.lagerberg@swedencare.se
Jenny Graflind, CFO
Tel: +46 (0)739-448 554, E-mail: jenny.graflind@swedencare.se

Swedencare develop, produce, market and sell premium products on the global and fastgrowing market within animal healthcare for cats, dogs and horses. The product groups ProDen PlaqueOff and NutriScience are represented on approximately fifty markets in all parts of the world, including the headquarter in Malmö, six subsidiaries in the Nordics, United States, France, Spain, Great Britain and Ireland and through an external distribution network. Swedencare’s sales have increased significantly over the last few years with strong margins and results. The board of directors and the management have a wide and extensive experience of international marketing and sales.

This information is information that Swedencare AB (publ) is required to disclose in accordance with the EU Market Abuse Regulation and the Securities Market Act. The information was submitted for publication on October 22, 2020 08.30 CET.

Calendar Period: 2020/2021
Date Event
18 February, 2021 Yearend Report 2020
29 April, 2021 Interim Report Q1 2021
29 April, 2021 Annual General Meeting, Kl. 14:00, Medeon Science Park
29 July, 2021 Interim Report Q2 2021
28 October, 2021 Interim Report Q3 2021
Links to quarterly reports, annual reports
and prospectus for Swedencare AB (publ).

For the current price and other share-related information,
please refer to Nasdaq First North Growth Market.

Nasdaq First North Growth Market is an alternative marketplace operated by OMX Nordic Exchange Stockholm. Companies whose shares are traded on Nasdaq First North Growth Market are not obliged to comply with the same rules as listed companies, but a less extensive regulatory framework applied to preferably smaller companies and growth companies. A placement in a company whose shares are traded on Nasdaq First North Growth Market may therefore be more risky than a placement in a listed company. All companies whose shares are traded on Nasdaq First North Growth Market have a Certified Adviser that oversees the company’s compliance with Nasdaq First North Growth Market’s regulatory framework for providing information to the market and investors. Certified Adviser reviews companies whose shares are to be traded on Nasdaq First North Growth Market. OMX Nordic Exchange Stockholm accepts the application for admission to such trade.

   Click here for our current share price at Nasdaq First North Growth Market.

ISIN-code: SE0008294078
Shortname: SECARE

Certified Adviser:
FNCA Sweden AB – phone: +46(0)8 528 00 399 – Email: info@fnca.se – Address: Box 5807, 102 48 Stockholm, Sweden

Analysts and other monitoring
ABG Sundal Collier – Johan Brown – Email: Johan.Brown@abgsc.se – phone: +46(0)8 566 286 51

Dividend
Dividend policy
Swedencare will pay a dividend that takes into account the Group’s earnings development, consolidation and investment needs,
liquidity and financial position. The goal is to pay a dividend of 40 percent of the profit after tax.

Decision on dividend
The Annual General Meeting agreed on a dividend for the financial year 2019 of 0.70 SEK per share.

Ownership

Ownership structure per latest quarterly report
Name Shares Shareholding (%)
HÅKAN SVANBERG & CO HEALTH CARE AB 4,631,455 23.99%
DNCA INVESTMENTS 1,526,136 7,91%
JCC GROUP INVEST SWEDEN AB (Johan Bergdahl through bolag) 1,517,351 7.86%
MASTAN AB (Håkan Lagerberg through bolag) 1,110,362 5.75%
AMF AKTIEFOND SMÅBOLAG 926,000 4,80%
SEB NANOCAP 734,172 3.80%
AKTIA ASSET MANAGMENT 658,873 3.41%
SHB FONDER 618,000 3.20%
JOH. BERENBERG, GOSSLER & CO. KG ACT OBO UNIVERSAL INV. FUNDS 585,822 3.04%
ENTER SMÅBOLAGSFOND 326,710 1,69%
INVESTMENT AB SPILTAN 300,000 1.55%
MARTIN SHIMKO – MD Swedencare USA 290,000 1.50%
CONSENSUS SMÅBOLAG 272,000 1,41%
RBC INVESTOR SERVICES BANK S.A 245,000 1,27%
NORDNET PENSIONSFÖRSÄKRING AB 238,289 1.23%
ML, PIERCE FENNER & SMITH INC. 222,173 1,15%
SWEDBANK ROBUR MICROCAP 220,000 1,14%
IKC FONDER AB 207,000 1,07%
LANNEBO NANOCAP 205,000 1,06%
HANS PERSSON – MD Swedencare France 199,750 1,03%
TEDCAP AB (Thomas Eklund through bolag) 190,000 0,98%
FONDITA NORDIC MICRO CAP INVESTMENT 184,769 0.96%
GRANDEUR, FUND BBHBOS 170,982 0.89%
BFCM P/C BFCM SWEDEN RETAIL LT 162,775 0,84%
CBNY-MKPGUE NAB ACF PIE GROWTH UK 160,000 0,83%
AVANZA 124,891 0.65%
PER MALMSTRÖM CONSULTING AB 123,000 0,64%
CBNY-MKJGRO NAB ACF JUNO KIWISAVER 100,000 0,52%
Others 3,051,470 15.81%
Total 19,301,980 100%
Free Float* 11,694,812 60,59%

Holdings include related parties.
* Shares not owned by board members, management, their affiliates, or shareholders with more than 10%.

Ownership structure per latest month

10 Largest shareholders
Name Shares Shareholding (%) Votes (%)
HÅKAN SVANBERG & CO HEALTH CARE AB 4,631,455 23.00% 23.00%
BNP PARIBAS SEC SERV LUXEMBOURG, W8IMY 1,544,711 7.67% 7.67%
JCC GROUP INVEST SWEDEN AB 1,517,351 7.54% 7.54%
MASTAN AB 1,097,352 5.45% 5.45%
AMF AKTIEFOND SMÅBOLAG 926,000 4.60% 4.60%
SEB NANOCAP 734,172 3.65% 3.65%
STATE STREET BANK AND TRUST CO, W9 594,932 2.95% 2.95%
SIX SIS AG, W8IMY 588,769 2.92% 2.92%
HANDELSBANKEN MICROCAP SVERIGE 507,750 2.52% 2.52%
SIJOITUSRAHASTO AKTIA NORDIC MIC 390,000 1.94% 1.94%
Others 7,602,251 37.76% 37.76%
Sum 2020-10-30 20,134,743 100% 100%

Geographical distribution
Country Amount of owners Shares Shareholding (%) Votes (%)
SWEDEN 5,301 13,364,858 66.38% 66.38%
LUXEMBURG 13 2,154,233 10.70% 10.70%
UNITED STATES 19 1,684,209 8.36% 8.36%
FINLAND 78 982,853 4.88% 4.88%
SWITZERLAND 10 930,181 4.62% 4.62%
FRANCE 3 445,347 2.21% 2.21%
UNITED KINGDOM 17 298,379 1.48% 1.48%
GERMANY 4 101,266 0.50% 0.50%
BELGIUM 4 42,431 0.21% 0.21%
SINGAPORE 2 40,100 0.20% 0.20%
NORWAY 14 35,526 0.18% 0.18%
LIECHTENSTEIN 1 30,231 0.15% 0.15%
IRELAND 7 12,542 0.06% 0.06%
Other countries 41 12,587 0.07% 0.07%
Sum 2020-10-30 5,514 20,134,743 100% 100%

Holdings
Ownership distribution by holding Amount of owners Shares Shareholding (%) Votes (%)
1 – 500 5,026 371,995 1.85% 1.85%
501 – 1000 203 161,826 0.80% 0.80%
1001 – 2000 131 199,115 0.99% 0.99%
2001 – 5000 53 181,448 0.90% 0.90%
5001 – 10000 21 158,553 0.79% 0.79%
10001 – 20000 12 177,549 0.88% 0.88%
20001 – 50000 23 847,145 4.21% 4.21%
50001 – 100000 13 1,005,462 4.99% 4.99%
100001 – 500000 23 4,889,158 24.28% 24.28%
500001 – 1000000 5 3,351,623 16.65% 16.65%
1000001 – 5000000 4 8,790,869 43.66% 43.66%
Sum 2020-10-30 5,514 20,134,743 100% 100%

Concentration

*Per 2020-10-30

Type of Concentration Concentration Shareholding (%) Votes (%) Shares
The 10 largest owners 10 62.24% 62.24% 12,532,492
The 20 largest owners 20 75.66% 75.66% 15,233,420
The 30 largest owners 30 83.51% 83.51% 16,814,684
Links to public presentations
of Swedencare AB (publ).
Date Description Download Video
7 September, 2020 Swedencare AB (publ) – Swedencare at ABGSC Investor Day 2020
2 September, 2020 Swedencare AB (publ) – Swedencare at Pareto Securities Annual Healthcare Conference 2020
10 June, 2020 Swedencare AB (publ) – Swedencare at Handelsbanken Nordic Mid Small Cap Seminar 2020
3 September, 2019 Swedencare AB (publ) – Swedencare at Introduce Investor Days 2019 (Q2 2019)
3 September, 2019 Swedencare AB (publ) – Interview with CEO Håkan Lagerberg at Introduce Investor Days 2019 (Q2 2019)
15 March, 2019 Swedencare AB (publ) – Sit-down interview with CEO Håkan Lagerberg (Q4 2018)
15 March, 2019 Swedencare AB (publ) – Company presentation with CEO Håkan Lagerberg (Q4 2018)
4 September, 2018 Swedencare AB (publ) – Sit-down interview with CEO Håkan Lagerberg (Q2 2018)
4 September, 2018 Swedencare AB (publ) – Company presentation with CEO Håkan Lagerberg (Q2 2018)
26 April, 2018 Swedencare AB (publ) – Interview with CEO Håkan Lagerberg (Q1 2018)
20 April, 2018 Swedencare AB (publ) – Remiums analys till institutioner, köp riktkurs 44 SEK
11 September, 2017 Swedencare AB (publ) – Investor Presentation SvD Börsplus 11 Sept 2017
30 August, 2016 Swedencare AB (publ) – Interim Report (Q2 2016)
21 April, 2016 Swedencare AB (publ) – Company Presentation
Content

Extra bolagsstämma 2020

Extra bolagsstämma 2020

Årsstämma 2020

Årsstämma 2020

Legal Organization /
Board and Management.

Swedencare AB (publ)-Legal Organization

Swedencare

The parent company Swedencare AB (publ) is responsible for the strategy, business planning and management. This is done by the control of trademarks and patents, sales rights, cooperation agreements and as parent company of the subsidiaries. The Company and headquarter is located at Medeon Science Park in Malmö, Sweden.

Subsidiaries/Sales Company

Swedencare owns 100% of the shares to all subsidiaries/sales companies which are responsible for the sales and marketing for its individual regions. The subsidiaries provide a monthly financial report as well as a sales progress to Swedencare. The group also have a common ERP-system where orders and invoices are registered. The system enable an effective production planning at the same time as the subsidiaries can track the order progress. Through the local market knowledge of the subsidiaries the marketing can be customized and the local customer preferences and new products can easily and effectively be identified. The subsidiaries are located and managed in Greece, Spain, France, Great Britain, Ireland, Sweden and the US.

Board of Directors (BoD) and Management

The Board of Directors are responsible for the Company’s strategic and financial targets and, together with the management, for the strategic planning. In the BoD, there is an extensive experience of international sales and marketing as well as a wide international network. The Managing Director and CFO are responsible to provide a business plan in line with the BoDs strategic and financial targets. They are also responsible for financial planning, and questions and communication with the stock exchange. The CEO of the Company, together with the managing directors of the subsidiaries, is a management team responsible for product development as well as sales and marketing.

Board of Directors of Swedencare

Swedencare AB (publ)-Board-Members

Swedencare AB (publ)-Board-Member-Per-Malmstrom
Per Malmström
President of the Board since 2014 – Born 1961.

•  Background from the financial sector, among others SEB, Aragon Fondkommission, CFO at Adera AB 1998-2001 (Addnode AB), as well as several Board assignments. Bachelor of economics from Örebro Högskola.

•  Managing Director and member of the board at Per Malmström Consulting AB. President of the board in K3 Nordic AB, K3 Travel AB, SVANBERG & CO INVEST AB, Creative Tools, Northway Partners, Deligate AB.

Independent in relation to the company/company management: Yes
Independent in relation to the company’s major owners: No
Holding*:  123 000 shares

Swedencare AB (publ)-Board-Member-Hakan-Lagerberg
Håkan Lagerberg
Member of the board since 2014 – Born 1968.

•  International experience from leading positions in private and public companies. International Jur. Kand from Lunds University. Post graduate in International Trade Law from University of Torino in Italy.

•  Chairman of the Board of One CC AB. Member of the Board of Directors of Polygiene AB (publ), HAOLAG AB and Mastan AB.

Independent in relation to the company/company management: No
Independent in relation to the company’s major owners: No
Holding*:  1 110 362 shares

Swedencare AB (publ)-Board-Member-Johan-Bergdahl
Johan Bergdahl
Member of the board since 2014 – Born 1970.

•  Entrepreneur and owner to several companies within sales, IT and property management. Degree in Market economy from Nercia Business School.

•  President of the board in Local Market Sweden AB and BR Group AB. Member of the board in Comera AB, JCC Group AB, JCC Group Invest AB, Junikvisten 10 AB, Rostastrand Holding AB, BR Group Holding AB, BR Group Fastigheter AB, Storgatan Fastigheter AB and Trygghandel AB.

Independent in relation to the company/company management: Yes
Independent in relation to the company’s major owners: No
Holding*:  1 517 351 shares

Swedencare AB (publ)-Board-Member-Tomas-Eklund
Thomas Eklund
Member of the board since 2016 – Born 1967.

•  Advisor to Patricia AB (Investor AB) and former Managing Director of Investor Growth Capital in Europe.
Extensive experience of investments and business development within the healthcare market.
•  Chairman of the Board of Sedana Medical AB (publ).

•  Board member of Boule Diagnostics AB, Biotage AB, Rodebjer Form AB and Immedica Pharma AB.

Independent in relation to the company/company management: Yes
Independent in relation to the company’s major owners: Yes
Holding*:  190 000 shares

Swedencare AB (publ)-Board-Member-Hakan-Svanberg
Håkan Svanberg
Member of the board since 2014 – Born 1957.

•  Entrepreneur and owner to several companies within IT, travel and finance. Master in Philosophy from Örebro University.

•  Managing Director in SVANBERG & CO INVEST AB. Member of the board in Creative Tools, Deligate AB, EyeonID Group AB, K3 Nordic AB, SVANBERG & CO INVEST AB, H. Svanberg Software Holding, Northway Partners, Svanberg Factoring, Treberg Holding AB, Kontosmart AB. Deputy of the board in Chief Holding AB and SWG Holding AB.

Independent in relation to the company/company management: Yes
Independent in relation to the company’s major owners: No
Holding*:  4 631 455 shares

Swedencare AB (publ)-Board-Member-Sara-Brandt
Sara Brandt
Member of the board since 2019 – Born 1963.

•  Vice President Almi Företagspartner, former VP and CEO Berner Nordic and before that senior positions on ia. Cederroth Nordic, Coca-Cola Sweden, Unilever Nordic and UK. Long background from international B2C and B2B companies and broad experience from several industries and product categories such as consumer health and international distributor activities.
Board member of ClearOn and Almi Skåne.

Independent in relation to the company/company management: Yes
Independent in relation to the company’s major owners: Yes
Holding*:  –

Own or related holdings of shares and other financial instruments in Swedencare. Holding by September 30, 2020.

Management
hakan-lagerberg
Håkan Lagerberg
CEO

•  See info above.

jenny-graflind
Jenny Graflind
CFO

•  Jenny has been employed since 2017.

•  A long international background as CFO and previously as, among other functions Financial Controller
and auditor of global groups, both privately owned as owned by private equity.
Bachelor of Science Management from Florida Atlantic University.

Board member of USWE.
Number of Shares in Swedencare:  35 000 shares.

Responsible at Swedencare’s subsidiaries
john-leonard
John Leonard
MD of the subsidiaries Swedencare UK Ltd and Swedencare Ireland

•  John has been employed since 2004.

•  Over 20 years of experience from the Oralhealth industry as Sales Manager at TePe and Colgate and development manager at CTS dental.
HND Business & Finance from Teesside University.

No other assignments.
Number of Shares in Swedencare:  81 968 shares.

brian-nugent
Brian Nugent
MD of the subsidiary StratfordCare USA Inc

•  Brian has been employed since 2011.

•  Over 20 years experience as founder, COO and CEO of multiple successful animal health companies based in the United States.
Prior to Animal Health, Brian worked in Operations Management for the Tampa Bay Buccaneers of the National Football League (NFL).
Bachelor of Science in Multi-National Business Operations from the Florida State University.

No other assignments.
Number of Shares in Swedencare:  15 231 shares.

hans-persson
Hans Persson
MD of the subsidiary SARL Buccosanté

•  Hans is employed since 2008.

•  Experience of international marketing, distribution and sales as well as 25 years of experience in leading smaller companies in the French market.
Engineering degree and degree in market economy from Lund.

No other assignments.
Number of Shares in Swedencare:  199 750 shares.

Ioanna Psychogiou
Ioanna Psychogiou
Country Manager of the subsidiary Biovet

•  Ioanna has been employed since 2012.

•  Background as manager of Biovet and experience in the pet and veterinary markets.
Physics Degree and Master’s Degree in Electronic Telecommunication of Technology.

No other assignments.
Number of Shares in Swedencare:  31 358 shares.

martin-shimko
Matthew Shaw
MD of the subsidiary Nutravet UK Ltd

•  Matthew has been employed since 2008.

•  Entrepreneurial background across various sectors. Expertise in building brands with a keen eye for detail
particularly in product development, sales & marketing.
Founded Nutravet in 2008, which has grown to be the number 1 vet exclusive nutraceutical brand in the UK.

No other assignments.
Number of Shares in Swedencare:  580 769 shares.

martin-shimko
Martin Shimko
MD of the subsidiary SwedencareUSA Inc

•  Martin has been employed since 2005.

•  A background as management trainee from NASSCO and the management group in The Bohle Co.
Bachelor of Science in Engineering from the University of Michigan and a degree in accounting from the University of California LA.

No other assignments.
Number of Shares in Swedencare:  290 000 shares.

raquel-tosca
Raquel Tosca
Country Manager of the subsidiary Swedencare Spain SLU

•  Raquel has been employed since 2019.

•  An international background of international business, marketing and communication at the latest from the animal health company Laboratorios Calier. Master’s degree in Marketing, Communication & Digital Publicity from UOC University in Barcelona and Inesdi Digital Business School.

No other assignments.
Number of Shares in Swedencare:  -.

sabine-uhde
Sabine Uhde
Head of the Nordic subsidiary Swedencare Nordic AB

•  Sabine has been employed since 2015.

•  Background as department manager and from the marketing department on TT-line.
Associate Degree.

No other assignments.
Number of Shares in Swedencare:  -.

sabine-uhde
Jason Braun
MD of the subsidiary Animal Pharm Care USA Inc

•  Jason has been employed since 2003.

•  Over 25 years of experience from the animal health industry. Founder and MD of Animal Pharmaceuticals since 2003.
Degree from Florida Atlantic University.

No other assignments.
Number of Shares in Swedencare:  251 994 shares.

Articles of Association for
Swedencare AB (publ) (556470-3790)

§ 1 COMPANY NAME
The company name is Swedencare AB (publ). Public company.

§ 2 REGISTERED OFFICE
The registered head office of the company is in the municipality of Malmö.

§ 3 OBJECTS OF THE COMPANY
The company objective is, directly or indirectly, the development, manufacture and sale of products within the area of animal healthcare and preventive dental care and other business compatible therewith.

§ 4 SHARE CAPITAL
The share capital shall be not less than SEK 500,000 and not more than SEK 2,000,000.

§ 5 NUMBER OF SHARES
The number of shares shall be not less than 10,000,000 and not more than 40,000,000.

§ 6 FINANCIAL YEAR
The company’s financial year shall be calendar year.

§ 7 BOARD OF DIRECTORS
The board of directors shall consist of not less than three and not more than seven board members with not more than two deputy board members. The board members and deputy board members are elected annually for the period until the close of the first annual general meeting held after the year in which the board member or deputy board member was appointed.

§ 8 AUDITOR
For audit of the company’s annual report, the accounts and the administration of the board of directors and managing director, not less than one auditor and not more than two auditors with or without deputy auditors shall be elected.

§ 9 ANNUAL GENERAL MEETING

The following matters shall be addressed at the Annual General Meeting:

1. Election of a chairman at the meeting;

2. Preparation and approval of the voting list;

3. Election of one (1) or two (2) persons to verify the minutes of the meeting;

4. Approval of the agenda;

5. Determination of whether the meeting was duly convened;

6. Submission of the annual report and the auditor’s report, and if applicable, the group accounts and the auditor’s report for the group;

7. Resolutions:

(a) regarding the adoption of the income statement and balance sheet, and if applicable, the consolidated income statement and the consolidated balance sheet

(b) regarding allocation of profit or loss in accordance with the adopted balance sheet

(c) regarding the discharge from liability of the board members and, where applicable, of the managing director;

8. Determination of fees for the board of directors and, where applicable, for the auditors;

9. Election of the board of directors and auditors; and

10. Other matters which rest upon the meeting according to the Swedish Companies Act or the company’s articles of association.

§ 10 NOTICE TO ATTEND
Notice to attend a general meeting shall be advertised in Post- och Inrikes Tidningar (The Official Swedish Gazette) and on the company website. At the time of notice, information about the notice shall be advertised in Dagens Industri. The notice shall immediately, and at no cost for the recipient, be sent by post to those shareholders who so request and state their address.
Notice to attend an annual general meeting and notice to attend an extraordinary general meeting at which the issue of alterations of the articles of association is to be addressed shall be issued not earlier than six weeks and not later than four weeks prior to the meeting. Notice to attend an extraordinary general meeting other than such as mentioned above shall be issued not earlier than six weeks and not later than two weeks prior to the general meeting.

§ 11 APPLICATION IN ADVANCE
A shareholder, who wishes to participate at the general meeting, shall (i) be included in the transcript or other record of the share register as of five days before the meeting (ii) notify the company thereof not later than on the date specified in the notice to attend the general meeting. Such a date may not be a Sunday, other public holiday, Saturday, Midsummer Eve, Christmas Eve or New Year’s Eve and may not occur earlier than the fifth weekday prior to the general meeting. If the notice to attend the general meeting does not state a last day for notification, then notification is not required in order to participate at the general meeting. A shareholder who wishes to be accompanied by advisors at a general meeting shall state the number of advisors (not more than two) accompanying the shareholder in the application.

§ 12 CSD CLAUSE
The company’s shares shall be registered in a CSD (central securities depository) register in accordance with the Financial Instruments (Accounts) Act (1998:1479).

Articles of Association adopted at the general meeting held on March 7, 2016.

Audit

At the 2019 Annual General Meeting, the authorized auditing firm Grant Thornton Sweden AB was reappointed for an additional one-year period up to and including the 2020 Annual General Meeting.

The auditor reviews the company’s annual report, interim report for the second quarter and accounting, as well as the Board’s and the CEO’s administration.

Swedencare’s AUDITOR
Ann Theander

Principal auditor
Authorized Public Accountant at Grant Thornton Sweden AB.
Auditor in the group since 2018.

Swedencare AB (publ)
Follow Swedencare’s news feed


Sign up for our news
and press releases

Stay up-to-date with the latest news about us, delivered right to your inbox!